In March 2024, the U.S. Food and Drug Administration (FDA) approved the first over-the-counter CGMs for people without diabetes, expanding access to this technology. Companies like Dexcom and Abbott lead the market, offering devices that cost approximately $50 per sensor, with each lasting about two weeks, resulting in a monthly cost of around $100. These devices are now marketed not only to those with diabetes but also to individuals seeking to optimize their health by understanding how diet and lifestyle affect their glucose levels.
